Introduction
Two unsung hero hormones—Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) have emerged as targets for groundbreaking therapies that reshape the way we approach diabetes treatment and weight loss management.
GLP-1 and GIP are secreted in response to food intake, and are insulinotropic (have the ability to stimulate the release of insulin, orchestrating the regulation of blood sugar, appetite, and energy balance in the body.
These hormones once existed in the background of scientific understanding, their potential hidden beneath layers of physiological complexity. Yet, their discovery and subsequent manipulation have led to groundbreaking therapies.
The Discovery of Incretins
The story begins in the 1960s, when scientists identified GIP, originally termed “gastric inhibitory polypeptide,” for its role in modulating gastric acid secretion. However, its true nature was revealed when researchers discovered its powerful ability to enhance insulin secretion in response to glucose, leading to its reclassification as an incretin hormone. Incretins stimulate secretion of insulin and decrease blood glucose levels after eating.
Two decades after the discovery of GIP, GLP-1 emerged as another key player, secreted by L cells in the gut in response to food intake. Together, these hormones became known for their role in amplifying the body’s insulin response—a phenomenon termed the incretin effect—whereby oral glucose triggered a far greater insulin release than glucose administered intravenously.
Despite their shared mission, GLP-1 and GIP possess distinct attributes. GLP-1 not only stimulates insulin secretion but also suppresses glucagon release, and promotes satiety. GIP, on the other hand, demonstrated insulinotropic properties but exhibited a paradoxical effect on glucagon secretion, stimulating glucagon release during low blood sugar conditions. This duality intrigued scientists and raised questions about the full potential of these hormones in disease management.
Harnessing the Power of GLP-1: A Leap Forward in Diabetes Therapy
The therapeutic implications of GLP-1 quickly became apparent. Scientists sought ways to extend its naturally short half-life, as it was rapidly degraded by the enzyme dipeptidyl peptidase-4. This quest led to the development of GLP-1 receptor agonists (GLP-1RAs), synthetic molecules that mimic the hormone’s actions while resisting degradation.
The breakthrough came from an unlikely source—the venom of the Gila monster lizard. Within its potent mix of bioactive molecules, researchers identified exendin-4, a peptide with remarkable similarity to human GLP-1 but with prolonged activity. This discovery led to the development of exenatide, the first GLP-1RA approved for Type 2 Diabetes treatment. Following this, liraglutide and semaglutide emerged, demonstrating superior glucose control, weight loss, and cardiovascular benefits, positioning GLP-1RAs as a cornerstone in diabetes management.
The GIP Enigma: A Surprising Revival
Unlike GLP-1, GIP faced a more uncertain fate. Early studies suggested that in individuals with Type 2 Diabetes, the insulinotropic effect of GIP was significantly blunted. This finding dampened enthusiasm for GIP-based therapies, as its ability to regulate glucose seemed compromised in diabetic patients.
However, science is seldom linear. Further investigations revealed that GIP’s effects were not entirely diminished, rather, its potential lay in combination therapy. Researchers hypothesized that pairing GIP with GLP-1 could yield synergistic benefits, leading to the development of dual receptor agonists that could harness the strengths of both hormones.
The Dawn of Dual Agonists: A New Frontier
The idea of targeting both GIP and GLP-1 receptors in a single molecule took shape in the form of tirzepatide, the first unimolecular dual incretin agonist. Tirzepatide’s ability to activate both GIP and GLP-1 receptors resulted in unprecedented weight loss and glycemic control, surpassing even the most effective GLP-1RAs. In a pivotal clinical trial, tirzepatide demonstrated remarkable efficacy, achieving superior HbA1c reductions (a marker of excess of blood glucose) and weight loss compared to semaglutide. The once-dismissed GIP had now become a key ingredient in one of the most powerful metabolic therapies to date. The dual action mechanism suggested that GIP might amplify the metabolic effects of GLP-1, improving insulin sensitivity, enhancing fat metabolism, and even reducing cardiovascular risk factors.
Beyond Diabetes: Expanding the Horizons of Incretin Therapy
As research continued, scientists uncovered additional benefits of GLP-1 and GIP receptor activation beyond glycemic control. These hormones influence multiple physiological systems, making them attractive therapeutic targets for conditions beyond diabetes:
Obesity Management: GLP-1RAs like semaglutide and dual agonists like tirzepatide have impacted obesity treatment, with patients experiencing up to 20% weight loss in clinical trials.
Cardiovascular Protection: GLP-1RAs have demonstrated cardiovascular benefits, including reductions in major adverse cardiovascular events, improved blood pressure control, and enhanced lipid metabolism.
Neuroprotection: Emerging evidence suggests that incretin hormones may play a role in neurodegenerative diseases such as Alzheimer’s disease, offering potential therapeutic avenues beyond metabolic disorders.
Challenges and the Future of Incretin-Based Therapy
Despite their promise, incretin-based therapies face challenges. Gastrointestinal side effects, such as nausea and vomiting, remain a common concern. Additionally, the long-term safety and sustainability of these therapies require further investigation, particularly as demand surges globally.
Yet, the future remains bright. With ongoing advancements in triple agonists—which target GLP-1, GIP, and glucagon receptors simultaneously—scientists are pushing the boundaries of metabolic medicine even further. These innovations could unlock even greater weight loss, enhanced glucose control, and broader applications across metabolic diseases.
Conclusion: The Next Chapter in Metabolic Medicine
The journey of GLP-1 and GIP from physiological curiosities to therapeutic powerhouses is a testament to the ever-evolving nature of scientific discovery. What began as an exploration of two hormones has blossomed into an entirely new era of metabolic treatment, reshaping the way we approach diabetes, obesity, and beyond.
As research continues to unravel the complexities of incretin biology, one thing is clear: the story of GLP-1 and GIP is far from over. With each new discovery, the promise of more effective, personalized, and transformative treatments inches closer to reality, offering hope to millions worldwide who struggle with metabolic disorders.
Citation
1.Liu, Q.K, Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology 15:1431292, 2024.
doi: 10.3389/fendo.2024.1431292
About Marin Biologic Laboratories
Our Recent Publication/Meeting Presentation on Gene Therapy
1. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
2. American Society of Hematology (ASH) Annual Meeting 2024.
Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise
With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.
Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.
Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories
Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)
Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)
- ADME/Tox
- Molecular Biology
- The Art of Cell Culture
- Exosomes
- Stability Services
- Potency Assay
- Gene Therapy Assays
- Immunotherapy Assays
- Antiviral Therapy Assays
- cGMP
- MLR
- Cell Based Assays
- ELISA
- Flow Cytometry
- Protein
- PCR-qPCR
- Immunoassay
- Radioimmunoassay
- GLP
- Transfection
- Cell Therapy Assays
- Targeted Protein Degradation
- Research to Commercialization
